No Data
No Data
Apogee Therapeutics Director Mark McKenna Acquires $990,775 in Stock
Guggenheim Reiterates Buy on Apogee Therapeuticsto Buy
Apogee Therapeutics Advances Clinical Trials for APG333
Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025
Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, Its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
Unlock the Full List